Who are Anhydrous Amiloride Hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chlorthalidone plus amiloride, Midamor, spironolactone, beta-blockers,ecc, Aldactone, Spironolactone (drug), Phase C: Spironolactone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anhydrous-amiloride-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anhydrous Amiloride Hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anhydrous Amiloride Hydrochloride (Anhydrous Amiloride Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-sparing diuretic. Area: Cardiovascular.

marketed Potassium-sparing diuretic Epithelial sodium channel (ENaC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Anhydrous Amiloride Hydrochloride (Anhydrous Amiloride Hydrochloride) — Assistance Publique - Hôpitaux de Paris. Amiloride is a potassium-sparing diuretic that blocks sodium reabsorption in the collecting duct of the nephron, thereby increasing sodium and water excretion while retaining potassium.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anhydrous Amiloride Hydrochloride TARGET	Anhydrous Amiloride Hydrochloride	Assistance Publique - Hôpitaux de Paris	marketed	Potassium-sparing diuretic	Epithelial sodium channel (ENaC)
Chlorthalidone plus amiloride	Chlorthalidone plus amiloride	Hospital de Clinicas de Porto Alegre	phase 3	Thiazide-like diuretic plus potassium-sparing diuretic combination	Na-Cl cotransporter (chlorthalidone); epithelial sodium channel ENaC (amiloride)
Midamor	AMILORIDE	Padagis Us	marketed	Potassium-sparing Diuretic	Amiloride-sensitive sodium channel, ENaC	1981-01-01
spironolactone, beta-blockers,ecc	spironolactone, beta-blockers,ecc	University of Roma La Sapienza	marketed	Combination therapy: potassium-sparing diuretic + beta-adrenergic antagonist	Aldosterone receptor (mineralocorticoid receptor) and beta-adrenergic receptors (β1, β2)
Aldactone	Spironolactone	Pfizer Inc.	marketed	Potassium-sparing diuretic, aldosterone antagonist	Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule
Spironolactone (drug)	Spironolactone (drug)	University of Sao Paulo General Hospital	marketed	Potassium-sparing diuretic; Aldosterone antagonist	Mineralocorticoid receptor (MR)
Phase C: Spironolactone	Phase C: Spironolactone	National Institute of Cardiology, Warsaw, Poland	marketed	Potassium-sparing diuretic; Aldosterone antagonist	Mineralocorticoid receptor (MR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-sparing diuretic class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Astellas Pharma Europe Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anhydrous Amiloride Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/anhydrous-amiloride-hydrochloride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab